-The Hindu Haryana, Gujarat, Madhya Pradesh, Punjab and Maharashtra are the top States registering a rise in the number of COVID cases India’s indigenous COVID-19 vaccine Covaxin from Hyderabad-based Bharat Biotechis now authorised for emergency use on a par with Oxford-AstraZeneca’s Covishield, NITI Aayog’s member (health) V.K. Paul said on Thursday. India is now seeing a rise in the number of active cases after touching lowest mark in mid-February. Haryana, Gujarat, Madhya Pradesh,...

-The Indian Express The current scenario is ideal for policymakers and practitioners to drive home the importance of health spending and institutional development With the first batch of anti-COVID vaccines being rolled out, the mood of the nation seems to be upbeat as it bids farewell to the pain and anguish of last year. The emergency-use approval to the vaccine developed by Oxford University and the Swedish-British pharma major AstraZeneca, manufactured in...

-The Hindu Company releases fact sheet detailing possible adverse events and those who are eligible for the vaccine Those with any history of allergies, fever and bleeding disorder, on blood thinners and who are immunity compromised or on medication have been told by COVAXIN manufacturer Bharat Biotech not to take the vaccine. A statement uploaded on the company website on Monday said the vaccine was also contraindicated for pregnant/lactating women, those using other...

-The Hindu They advise against Covaxin, say there is no proof of efficacy. Several experts have raised concern over the “hasty approval” granted to the COVID-19 vaccines despite the lack of adequate efficacy data. The Central Drugs Standard Control Organisation on Sunday accorded approval for restricted emergency use of the Oxford COVID-19 vaccine Covishield, manufactured by the Serum Institute of India (SII), and the indigenously developed vaccine Covaxin of Bharat Biotech. “I’m completely unaware...

-Livemint.com India has adopted a cautious approach in granting approval to covid-19 vaccines as fast tracking, safety and efficacy remain primary concern NEW DELHI: Safety and efficacy are the primary concerns of the government while granting emergency use authorization (EUA) to any covid-19 vaccine in the country. The government's cautious approach before approving a vaccine is apparent. The meeting of the subject expert committee of Central Drugs Standards Control Organisation on Wednesday asked...